BioPharmSignal logoBioPharmSignal

Biotech News

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Virios Therapeutics (VIRI)Virios TherapeuticsPartnership

VIRI (VIRI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is viri.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VIRIVirios Therapeutics2026-04-15 13:00 EST

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

IMNNImunon2026-09-10 13:30 EST

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

OGENOragenics2026-05-07 12:30 EST

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

IMNNImunon2026-07-23 13:25 EST

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

View all latest news

Virios Therapeutics

Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy. Halneuron Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated...

Recent company news

VIRIVirios Therapeutics2026-09-14 12:45 EST

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

VIRIVirios Therapeutics2026-08-17 12:30 EST

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States